SOURCE-LINKED INTELLIGENCE

THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX

CORDIS · observation · Publication date unknown

warfare attack) context. In THANATOS, ArAv87 will be optimized to increase its affinity, its clinical tolerance, its manufacturability and its stability. An original and efficient approach combining artificial intelligence and gold-standard conventional techniques of laboratory will be used to realize this optimization with a very limited time and funds. Optimized ArAv87 antibody will be tested in vivo against mpox in mice and non-human primate model. Then, the preclinical development of optimized ArAv87 will be realized, to guaranty the safety and efficacy of the antibody before the first-in-human study. After the production under GMP conditions, the clinical safety of this antibody will be evaluated in a clinical trial phase 1 in cohorts of healthy volunteers. mpox, therapeutic antibody, neutralizing antibody, monkeypox virus, variola major, prophylactic antibody, pandemic, epidemic, biofesense, medical countermeasure, orthopoxvirus, biohazard, biowarfare

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

13557640.83

unit

EUR